PET-Technology, a RUSNANO Portfolio Company, has Opened its 10th Nuclear Medicine Centre

16 March 2018

PET-Technology’s national network of nuclear medicine centres, created with the participation of RUSNANO, has opened its 10th centre in Samara. In addition to cancer diagnostics the Centre will, for the first time in Russia, provide cardiovascular PET/CT diagnostics. Investment in the Samara Centre exceeded 410 mln roubles, and the total investment in the national network of PET-Centres has now reached 4.4 bln roubles.

The opening ceremony was attended by Anatoly Chubais, Chairman of the Executive Board of RUSNANO Management Company, Vladimir Avetisyan, Deputy Chairman of the Executive Board of RUSNANO Management Company, Dmitry Azarov, acting Governor of the Samara Region, Sergey Notov, Chairman of the Board of Directors of IPT Group, and Diana Kobesova, CEO of PET-Technology.

Annually the new Centre will be able to perform 5,000 diagnostic procedures, 90 percent of which will be available under the state OMS (compulsory health insurance) system. The Samara Region is the only region with two PET-technology Centres: the first such centre opened in Togliatti less than six months ago. The two centres together can carry out up to 10,000 diagnostic procedures per year.

The Centre is located on the premises of the Samara region oncology dispensary. It will soon start carrying out cardiological PET/CT studies for the most common diseases: coronary heart disease and myocardial infarction, as well as assessments for bypass surgery.

PET-Technology is the first company in Russia to implement “full cycle” nuclear medicine—from the production of radiopharmaceuticals and ensuring their availability throughout the country, to carrying out PET/CT diagnostics and “Cyber knife” treatments and the implementation of a patient monitoring system.

Anatoly Chubais, Chairman of the Executive Board of RUSNANO Management Company, said: “The Centre is now the tenth in the national network and its opening was the final stage in the creation of a large-scale diagnostic hub which combines the production of radiopharmaceuticals in Ufa and diagnostic centres in Ufa, Togliatti, Yekaterinburg and Samara. Including the PET Centre in Samara, PET-Technology’s national network covers nine regions of Russia and provides more than 28 mln people with access to high-tech medical care.”

Dmitry Azarov, acting Governor of the Samara Region, said: “Public-private partnerships, of all types, are developing rapidly in the Samara Region. This is the most effective format in the fields of medicine and healthcare: the PET-Centre in Samara was opened within the planned timescale. A complete cancer treatment system is being created in the Region—the largest cancer centre in Povolzhye is located close to the new PET-Centre. They will work together to ensure timely diagnostics, high quality assessment of treatment methods and monitoring of patients’ condition.”

Diana Kobesova, CEO of PET-Technology: “We intend to dramatically improve the availability of high-quality diagnostics and treatment of cancer. To this end, we are implementing a strategy of opening PET/CT centres across the country, and the Centre in Samara completes the first cycle of this strategy. The next cycle assumes that by 2025, 25 centres will be in operation, providing access to high-tech diagnostics for 1/4 of the population of Russia.”

The Centre is equipped with high-level class diagnostic equipment—a Discovery PET/CT 610 scanner. This model allows a full-fledged study to be carried out in 16 minutes, which means that up to 30 patients can be tested a day.

The radiopharmaceuticals (RPH) necessary for the PET/CT diagnostics will be delivered from the company’s own PET-Technology production centre in Ufa. Deliveries will be carried out on a daily basis by road and air transport.

Additional information

Reference

RUSNANO Joint-Stock Company was founded in March 2011 through reorganization of state corporation Russian Corporation of Nanotechnologies. JSC RUSNANO contributes to implementation of the state policy on the development of the nanotechnology industry by investing directly and through investment funds of nanotechnology in financially effective high-technology projects providing the development of new production facilities in the Russian Federation. Its primary investment focus is in electronics, optoelectronics and telecommunications, healthcare and biotechnology, metallurgy and metalwork, energy, mechanical engineering and instrument making, construction and industrial materials, chemicals and petrochemicals. 100 percent of RUSNANO’s shares are state owned. Thanks to RUSNANO’s investments, there are currently 95 factories and R&D Centers opened in 37 regions in Russia.

Management of assets of RUSNANO JSC is carried out by Limited Liability Company established in December 2013, RUSNANO Management Company. Anatoly Chubais is the Chairman of its Executive Board.

Work to establish nanotechnology infrastructure and carry out educational programs is fulfilled by RUSNANO’s Fund for Infrastructure and Educational Programs, which was also established during the reorganization of the Russian Corporation of Nanotechnologies.

* * *

PET-Technology LLC, RUSNANO’s Portfolio Company, was founded in 2011 in order to implement the project “Establishment of a network of regional PET/CT Centers for diagnostic procedures”—Nuclear Medicine Centers.

Currently, there are 10 diagnostic centres in operation in Moscow, Kursk, Belgorod, Yekaterinburg, Ufa, Lipetsk, Orel, Tambov, Togliatti and Samara, as well as 2 PET-Technology production centres in Ufa and Yelets, which are equipped with a cyclotron complex, a laboratory for the synthesis of radiopharmaceuticals, equipment for dosing and packaging of RPH, as well as quality control equipment. These facilities allow PET-centres to use their own radiopharmaceuticals (RPH), which are promptly delivered to the centres’ patients.

The company’s overall goal is to increase the availability of highly effective methods of diagnosis and treatment of cancer in Russia. In accordance with the territorial strategy for the development of nuclear medicine centres, PET-Technology plans to open 10 new diagnostic centres by 2020, and 25 by 2025.